Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity
ChemBioChem · 2023
DOI: 10.1002/cbic.202300141 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2023. Verfasst von Eriko Koide und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Proteolysis Targeting Chimera, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Focal adhesion kinase (FAK) is an attractive drug target due to its overexpression in cancer. FAK functions as a non‐receptor tyrosine kinase and scaffolding protein, coordinating several downstream signaling effectors and cellular processes. While drug discovery efforts have largely focused on targeting FAK kinase activity, FAK inhibitors have failed to show efficacy as single agents in clinical trials. Here, using structure‐guided design, we report the development of a selective FAK inhibitor (BSJ‐04‐175) and degrader (BSJ‐04‐146) to evaluate the consequences and advantages of abolishing all FAK activity in cancer models. BSJ‐04‐146 achieves rapid and potent FAK degradation with high proteome‐wide specificity in cancer cells and induces durable degradation in mice. Compared to kinase inhibition, targeted degradation of FAK exhibits pronounced improved activity on downstream signaling and cancer cell viability and migration. Together, BSJ‐04‐175 and BSJ‐04‐146 are valuable chemical tools to dissect the specific consequences of targeting FAK through small‐molecule inhibition or degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
- Harvard Medical School, Boston, MA 02115, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Human Biology Division Fred, Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Cell Signaling Technology, Danvers, MA 01923, USA.
ORCID-Profile: Eriko Koide, Katherine A Donovan, Alissa J Nelson, Mike Aguiar, Eric S Fischer, Nathanael S Gray, Behnam Nabet
Förderung
- NCI NIH HHS
Zitieren
APA
Koide, E., Mohardt, M. L., Doctor, Z. M., Yang, A., Hao, M., Donovan, K. A., Kuismi, C. C., Nelson, A. J., Abell, K., Aguiar, M., Che, J., Stokes, M. P., Zhang, T., Aguirre, A. J., Fischer, E. S., Gray, N. S., Jiang, B., & Nabet, B. (2023). Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity. ChemBioChem. https://doi.org/10.1002/cbic.202300141
Vancouver
Koide E, Mohardt ML, Doctor ZM, Yang A, Hao M, Donovan KA, et al. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity. ChemBioChem. 2023. doi:10.1002/cbic.202300141
BibTeX
@article{Koide2023,
author = {Koide, Eriko and Mohardt, Mikaela L and Doctor, Zainab M and Yang, Annan and Hao, Mingfeng and Donovan, Katherine A and Kuismi, Christina C and Nelson, Alissa J and Abell, Kathryn and Aguiar, Mike and Che, Jianwei and Stokes, Matthew P and Zhang, Tinghu and Aguirre, Andrew J and Fischer, Eric S and Gray, Nathanael S and Jiang, Baishan and Nabet, Behnam},
title = {Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity},
journal = {ChemBioChem},
year = {2023},
doi = {10.1002/cbic.202300141}
}
EUVIMED